Evidence map›Paper›PMID 37818568›Full record

ReviewCurrent drug delivery2024

Deciphering the Therapeutic Applications of Nanomedicine in Ovarian Cancer Therapy: An Overview.

Pooja Mathur, Shailendra Bhatt, Suresh Kumar, Sweta Kamboj, Rohit Kamboj, Arpana Rana, Harish Kumar, Ravinder Verma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug delivery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Pooja MathurDepartment of Pharmacy, School of Medical and Allied Sciences, G.D. Goenka University, Gurugram-122103, India.
Shailendra BhattDepartment of Pharmacy, School of Medical and Allied Sciences, G.D. Goenka University, Gurugram-122103, India.
Suresh KumarDepartment of Pharmacy, School of Medical and Allied Sciences, G.D. Goenka University, Gurugram-122103, India.
Sweta KambojGuru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.
Rohit KambojGuru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.
Arpana RanaAdvanced Institute of Pharmacy, Delhi Mathura Road, Palwal-121105, India.
Harish KumarDepartment of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani-127021, India.
Ravinder VermaDepartment of Pharmaceutical Sciences, Chaudhary Bansi Lal University, Bhiwani-127021, India.ORCID 0000-0003-3397-703X
GD Goenka University · INChaudhary Devi Lal University · INGuru Gobind Singh Medical College and Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of deadly cancers that afflict the female reproductive system occur in the ovary. Around 1,40,000 women worldwide die from ovarian cancer each year, making it the sixth most common cancer-associated deceases among females in the United States. Modern, cutting-edge treatments like chemotherapy and surgery frequently produce full remissions, but the recurrence rate is still very high. When this crippling condition is diagnosed, there are frequently few therapeutic choices available because of how quietly it manifests. Healthcare practitioners must have a fundamental grasp of the warning signs and symptoms of ovarian cancer, as well as the imaging techniques and treatment choices available, to give the patient the best care possible. The discipline of medical nanotechnology has gained a lot of momentum in recent years in resolving issues and enhancing the detection and treatment of different illnesses, including cancer. This article gives a brief summary of types, risk factors and approaches to ovarian cancer treatment. We subsequently discussed the pathophysiology of ovarian cancer with the risk factors. This review also emphasizes the various signalling pathways involved in ovarian cancer. Our comprehensive integration of recent findings in fundamental research in the nano arena reveals the strong interest in these nanomedicines in ovarian cancer treatment. However, these nanomedicines still require more research, as indicated by the comparatively small number of clinical trials ongoing. This article will provide a reference for ovarian cancer treatment.

Indexed as

Antineoplastic AgentsNanomedicineOvarian NeoplasmsAnimalsFemaleHumansAntineoplastic AgentsnanomedicinesOvarian cancerpathophysiologyrisk factorssignaling pathwaytreatment.

Identifiers

PMID37818568
OpenAlexW4387516096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.